<DOC>
	<DOCNO>NCT00750334</DOCNO>
	<brief_summary>This study use determine maximum tolerate dose oral clofarabine administer daily 14 consecutive day repeat every 21 day .</brief_summary>
	<brief_title>A Study Oral Clofarabine Adult Patients With Myelodysplastic Syndromes ( MDS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<criteria>Provide sign , write informed consent . Be least 18 year old . Have pathologically confirm MDS score accord IPSS study entry . Pathologic confirmation responsibility investigator . Have treat previously MDS follow : a.Patients must least 1 , 2 , prior treatment regimen ; b.Patients must refractory ( i.e. , disease progression evidence response treatment ) 1 prior treatment regimen . Have Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Be able comply study procedure followup examination . Have adequate hepatic renal function . Be nonfertile agree use birth control study end last treatment visit least 90 day . Have readjustment dose and/or schedule erythropoietin , granulocyte colony stimulate factor ( GCSF ) growth factor within 8 week prior first dose oral clofarabine . Have chemotherapy investigational therapy MDS within 4 week first dose oral clofarabine . Have recover â‰¤ Grade 2 severity drugrelated nonhematologic toxicity prior first dose oral clofarabine . Have uncontrolled systemic fungal , bacterial , viral infection . Have history serious disease involve heart . Have clinically significant cardiac assessment screen know family history QT prolongation . Currently use medication know prolong QT interval . Have prior treatment clofarabine ( IV oral ) . Have diagnosis another malignancy , unless patient disease free least 3 year complete curative intent therapy except follow : . Patients treat nonmelanoma skin cancer , situ carcinoma , cervical intraepithelial neoplasia , regardless diseasefree duration , eligible study definitive treatment condition complete . b . Patients organconfined prostate cancer evidence recurrent progressive disease base prostate specific antigen ( PSA ) value also eligible study hormonal therapy initiate radical prostatectomy perform . Have prior positive test human immunodeficiency virus ( HIV ) . Have gastrointestinal disease prior surgery , may affect ability patient absorb oral clofarabine . Is currently participate another concurrent investigational protocol restrict data and/or sample collection patient demographic and/or disease purpose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Oral Clofarabine ,</keyword>
	<keyword>relapsed/refractory MDS ,</keyword>
	<keyword>Myelodysplastic</keyword>
</DOC>